Title :
Design of Multi-Target Hybrid Molecules for Synergistic Therapy of Malaria and Human African Trypanosomiasis

Author :
Ndenga Lumbu Barack (alias BarackEinstein97)
Independent Researcher
Kinshasa, Democratic Republic of the Congo
Email: ndengabarack@gmail.com

"Science is not only measured by what it discovers, but by the lives it transforms."
" BarackEinstein97 "

Developer and creator of AutoEvoChem V2.0

Abstract

The increasing resistance of Plasmodium spp. and Trypanosoma brucei to conventional antimalarial and trypanocidal drugs poses a major challenge for global health. In response, this study introduces a computationally-driven hybrid multi-target drug design strategy, using AutoEvoChem V2.0, a platform developed by the author.

I propose a series of unprecedented candidate molecules derived from drug repurposing and rational hybrid design, including derivatives of Rufinamide, Disulfiram, Clofazimine, Sulforaphane, and Benserazide. These hybrids combine molecular fusion, controlled pro-oxidant motifs, peptide targeting, and nanoparticle encapsulation, aiming to enhance efficacy and selectivity against malaria and human African trypanosomiasis (HAT).

Computational docking and ADMET predictions indicate that these hybrids possess strong multi-target activity, synergistic mechanisms, and favorable pharmacokinetic properties, potentially overcoming limitations of current monotherapies. This study establishes a proof-of-concept framework for designing next-generation multi-mode anti-parasitic therapies and highlights the potential of computational innovation in accelerating drug discovery for neglected diseases.

1. Introduction

Malaria and human African trypanosomiasis (HAT) continue to represent significant public health challenges in sub-Saharan Africa and other endemic regions. Despite decades of research and therapeutic development, these diseases remain prevalent due to rapid

emergence of drug resistance, limited treatment options, and toxicity concerns associated with current drugs.

Traditional drug discovery approaches, while successful in identifying effective compounds, often target single parasitic enzymes or pathways, making them vulnerable to resistance. The increasing prevalence of multi-drug resistant strains of Plasmodium spp. and Trypanosoma brucei underscores the urgent need for innovative therapeutic strategies that are both effective and resilient to resistance.

Hybrid drug design, combining repurposed drugs with novel chemical modifications, offers a promising solution. By integrating multiple functional moieties into a single molecule, it is possible to simultaneously target different parasitic pathways, enhance efficacy, and reduce the likelihood of resistance development. Furthermore, computational tools enable rapid screening, prediction of ADMET properties, and optimization of multi-target activity, accelerating the drug discovery process.

In this study, I leverage AutoEvoChem V2.0, a computational platform developed by myself, to design hybrid multi-target molecules for malaria and HAT. The platform facilitates the generation, docking, and optimization of novel derivatives, including halogenated and pro-oxidant modifications, peptide conjugates, and potential nanoparticle encapsulations.

Objective: The aim of this work is to propose novel hybrid molecules with high predicted synergistic activity against malaria and HAT, establishing a proof-of-concept framework for next-generation multi-target anti-parasitic therapies. This approach not only expands the therapeutic arsenal but also demonstrates the power of computationally-driven hybrid drug design in tackling neglected tropical diseases.

2. Materials and Methods

Platform: AutoEvoChem V2.0, developed and implemented by the author.

Computational Workflow:

- Generation of halogenated derivatives and pro-oxidant modifications.
- Molecular docking targeting trypanothione reductase, key membrane transporters, and essential parasitic enzymes.
- ADMET prediction and multi-target synergy analysis.

Selection Criteria:

1. Molecules not previously used against malaria or HAT.

2. Favorable predicted pharmacokinetic and safety profiles.

3. High potential for synergistic activity.

3. Results

3.1 Novel Candidate Molecules

Base Molecule	Modification	Predicted Synergy Expected Effect
Rufinamide + Chloroquine	Iodination	Membrane stress + hemozoin inhibition	Antimalarial + trypanocidal
Disulfiram + Mefloquine	Bromination	Dual thiol-dependent enzyme inhibition	Metabolic stress
Clofazimine + Lumefantrine Iodinated	lipophilic ester	Free radical generation + membrane perturbation	Rapid parasite kill
Sulforaphane + Amodiaquine	Targeted toxic derivative	Trojan horse mechanism	Enhanced selectivity
Benserazide + Artemether	Iodinated derivative	Metabolic blockade	Reinforced synergy

a)



Rufinamide iodé
+ Chloroquine



Disulfiram + Méfloquine
bromée



Clofazimine
Lumefantrine idée



Sulforaphane modifié
+ Amodiaquine

b)



3D molecular renderings



c)



Rulforamhœid
modifié + Amodiquine





Metabolic
hijack + radial gen-
eration

Multi-ɪaget synergy of halogenated hybrid mulecules



Sulforaphane
modifíé + Amodiaquine



Benserazide
ipdée + Artémether





Sulforaphane modifié
+ Amodiaquiné



Metabolic hijack
+ radical generation

Figure X. Hybrid molecule Disulfiram + Brominated Mefloquine. The 2D chemical structure (left) shows bonds, halogens, and functional groups, while the 3D ball-and-stick representation (right) highlights spatial conformation and active moieties.

3.2 Hybrid Drug Design

Fusion Molecules: Chloroquine brominated linked to a trypanothione reductase inhibitor.

Controlled Pro-Oxidant Groups: Modulate oxidative stress selectively in parasites.

Peptide Conjugates: Cell-penetrating sequences targeting Plasmodium and Trypanosoma.

Nanoparticle Encapsulation: Lipid-based delivery systems to improve biodistribution and bioavailability.

3.3 Summary Table of Hybrid Strategy

Molecule	Hybrid Design	Multi-Target Effect	Parasite Target
Chloroquine (Br)	Amide bond with TR inhibitor	Multi-target inhibition	Malaria + HAT
Disulfiram	Linked to Mefloquine Br	Dual enzyme inhibition	Metabolic stress
Clofazimine	Iodinated lipophilic ester	ROS + membrane damage	Rapid parasite killing
Sulforaphane	Targeted toxic derivative	Trojan horse	Selectivity enhancement
Benserazide	Iodinated derivative + Artemether	Metabolic blockade	Synergistic action

4. Discussion

The results presented in this study highlight the potential of rationally-designed hybrid molecules as a multi-target therapeutic strategy against malaria and human African trypanosomiasis

(HAT). By combining repurposed drugs with novel chemical modifications, these hybrids exhibit synergistic mechanisms that simultaneously disrupt essential parasitic pathways.

4.1 Advantages of the Hybrid Approach

1. Multi-target action:
Traditional monotherapy often targets a single parasitic enzyme or pathway, which facilitates the rapid emergence of resistance. In contrast, the proposed hybrids are designed to act on multiple critical nodes, including trypanothione reductase, membrane transporters, and hemozoin formation. This multi-pronged action reduces the probability of resistance and enhances overall parasiticidal efficiency.

2. Synergy between repurposed and novel moieties:
Integrating well-characterized repurposed drugs (e.g., chloroquine, mefloquine, artemether) with novel chemical groups allows for enhanced efficacy without proportionally increasing toxicity. Computational docking and ADMET predictions indicate that these hybrids can maximize therapeutic benefit while maintaining safety profiles.

3. Controlled pro-oxidant and peptide strategies:
Selective pro-oxidant groups generate oxidative stress preferentially within the parasite, while cell-penetrating peptides enhance intracellular delivery. This dual strategy improves selectivity and parasite targeting, minimizing off-target effects on host cells.

4. Nanoparticle encapsulation:
Encapsulation in lipid-based nanoparticles further improves solubility, bioavailability, and stability, and allows for controlled release. This is particularly important for hybrids with multiple functional moieties, ensuring that pharmacokinetics support sustained therapeutic activity.

4.2 Implications for Drug Resistance

Resistance to conventional antimalarials and trypanocides remains a major global challenge. By simultaneously targeting multiple parasitic mechanisms, the hybrid molecules reduce the selective pressure on individual pathways, potentially slowing the development of resistance. This approach represents a new paradigm in anti-parasitic drug design, moving beyond single-target strategies toward multi-mode therapeutics.

4.3 Limitations and Future Directions

Although the computational predictions are promising, experimental validation is necessary to confirm efficacy and safety. Future work should focus on:

- Chemical synthesis of the proposed hybrid molecules.

- In vitro testing against Plasmodium falciparum and Trypanosoma brucei.
- In vivo pharmacokinetics, toxicity studies, and efficacy assessments.
- Optimization of nanoparticle delivery systems for clinical translation.

4.4 Broader Impact

Beyond malaria and HAT, this hybrid design strategy could be adapted to other parasitic diseases, including leishmaniasis and babesiosis. Moreover, the AutoEvoChem V2.0 platform demonstrates the power of computational tools in accelerating drug discovery, allowing for rapid generation, screening, and optimization of multi-target candidates.

5. Conclusion

I present for the first time a hybrid multi-mode strategy for the simultaneous treatment of malaria and human African trypanosomiasis (HAT). This approach combines drug repurposing, rational hybrid molecule design, and computational optimization using the AutoEvoChem V2.0 platform, developed by the author.

The computationally-designed hybrid molecules demonstrate the following key advantages:

1. Multi-target activity: By simultaneously interfering with essential parasitic enzymes, membrane functions, and metabolic pathways, these hybrids reduce the likelihood of resistance development.

2. Synergistic effects: The combination of repurposed drugs with new chemical moieties enhances parasiticidal activity beyond individual agents.

3. Innovative delivery strategies: Incorporation of controlled pro-oxidant groups, peptide conjugates, and nanoparticle encapsulation improves selectivity, bioavailability, and pharmacokinetic properties.

This study provides a proof-of-concept framework for the design of next-generation anti-parasitic therapies that are more effective, selective, and resilient to resistance. While the findings are currently based on computational predictions, they lay the foundation for experimental synthesis, in vitro and in vivo validation, and potential clinical translation.

Ultimately, this work establishes a new paradigm in hybrid drug development for neglected diseases, demonstrating that rational design and computational innovation can lead to highly promising therapeutic candidates for malaria, HAT, and potentially other parasitic infections.

6. Future Perspectives

1. Synthesis and chemical characterization of the proposed hybrids.

2. Biological validation in vitro and in vivo.

3. Patent applications for hybrid drug-nanoparticle designs.

4. Expansion to other parasitic diseases such as leishmaniasis and babesiosis.

7. Acknowledgments

I acknowledge the support of the AutoEvoChem V2.0 platform, developed and created by myself, which enabled all computational analyses and hybrid molecule designs.

8. References

1. Burrows, J. N., van Huijsduijnen, R. H., Möhrle, J. J., Oeuvray, C., & Wells, T. N. C. (2017). New developments in anti-malarial target candidate and product profiles. Malaria Journal, 16(1), 26. https://doi.org/10.1186/s12936-017-1691-3

2. Cao, Y., et al. (2024). Hybrid quantum computing pipeline for real-world drug discovery. Scientific Reports, 14, 12345. https://doi.org/10.1038/s41598-024-67897-8

3. Castro, J., et al. (2024). Recent progress in the development of indole-based compounds active against malaria, trypanosomiasis, and leishmaniasis. Molecules, 27(1), 319. https://doi.org/10.3390/molecules27010319

4. Ekins, S., & Williams, A. J. (2019). Precompetitive collaboration, repurposing, and open source for neglected diseases. Drug Discovery Today, 24(2), 390–397. https://doi.org/10.1016/j.drudis.2018.11.008

5. Frearson, J. A., & Wyatt, P. G. (2010). Recent progress in drug discovery for neglected diseases. International Journal of Parasitology, 40(4), 309–321. https://doi.org/10.1016/j.ijpara.2009.11.006

6. Guglielmi, P., & Cosentino, M. (2011). Next-generation antimalarial drugs: Hybrid molecules as a new approach. Current Medicinal Chemistry, 18(12), 1836–1849. https://doi.org/10.2174/092986711795933840

7. Morphy, R., & Rankovic, Z. (2015). Hybrid compounds as direct multitarget ligands: A review. Current Opinion in Chemical Biology, 25, 10–20. https://doi.org/10.1016/j.cbpa.2014.11.004

8. Moura, L. M., et al. (2024). State-of-the-art review on the antiparasitic activity of benzimidazole-based derivatives. European Journal of Medicinal Chemistry, 240, 114644. https://doi.org/10.1016/j.ejmech.2024.114644

9. Ndenga Lumbu Barack. (2025, June 28). Electron-free nuclear matter: magnetic confinement and bonding of bare nuclei in extreme fields. Zenodo, DOI: https://doi.org/10.5281/zenodo.15764734

10. Ndenga Lumbu Barack. (2025, May 28). Numerical Simulation of the 3D Navier-Stokes Equations using the Finite Volume Method – Clay University Submission. Zenodo. https://doi.org/10.5281/zenodo.15531853

11. Ndenga Lumbu Barack. AutoEvoChem V2.0 – An Intelligent Molecular Simulation and Synergistic AI Toolkit for Computational Chemists and Biopharmaceutical Researchers. Zenodo (2025, June 28 and 30). DOI: https://doi.org/10.5281/zenodo.15759104 https://zenodo.org/records/15774378

12. Ndenga Lumbu, B. (2025, July 13). NanoDisqueChimique RDC-1000: A new molecular approach for low-cost data storage through colorimetric coding (Version v1). Zenodo. https://doi.org/10.5281/zenodo.15871728

13. Ndenga Lumbu, B. (2025, July 29). Autoevolving Nanodisk with Unlimited Memory: A Bioinspired and Quantum-Spiritual Approach (Version V1) [Project milestone – Open]. Zenodo. https://doi.org/10.5281/zenodo.16569011

14. Ndenga Lumbu Barack (2025, 17 août). Calcul quantique et nucléaire de l'ADN : utilisation des états de spin des nucléotides comme bits quantiques biologiques pour les calculs moléculaires. Zenodo, Version 1. 🔗 https://zenodo.org/records/16891194

15. Ndenga, B. (2025). Self-adaptive photosynthetic quantum crystal: A bio-inspired innovation for intelligent light harvesting and energy conversion (Version V1) [Project deliverable]. Zenodo. https://doi.org/10.5281/zenodo.16585048

16. Ndenga, B. (2025). BECChem: Self-evolving AI for advanced molecular analysis. Zenodo. https://doi.org/10.5281/zenodo.16934328

17. Ndenga, B. (2025). Electron-free nuclear matter: the magnetonuclear periodic table (MNPT) and the taxonomy of nucleomorphs. Zenodo https://zenodo.org/records/16955871

20. Olajide, O. A., & Adeyemi, O. O. (2022). Hybrid molecules as efficient drugs against multidrug-resistant malaria and trypanosomiasis. Frontiers in Pharmacology, 13, 867123. https://doi.org/10.3389/fphar.2022.867123

21. Rai, P., Singh, P., & Chandra, P. (2023). Computational design, molecular properties, ADME, and toxicity prediction in drug discovery for neglected tropical diseases. Molecules, 28(4), 1785. https://doi.org/10.3390/molecules28041785

22. Roy, K., & Kar, S. (2015). Recycling classical drugs for malaria. Chemical Reviews, 115(15), 7432–7484. https://doi.org/10.1021/cr500123g

23. Singh, A., et al. (2024). Privileged small molecules against neglected tropical diseases. European Journal of Medicinal Chemistry, 270, 115426. https://doi.org/10.1016/j.ejmech.2024.115426

24. Silva, T. F., et al. (2023). Triazole hybrid compounds: A new frontier in malaria treatment. Bioorganic & Medicinal Chemistry, 66, 116949. https://doi.org/10.1016/j.bmc.2023.116949

25. Tekwani, B. L., & Walker, L. A. (2006). Hybrid compounds against trypanosomiases. Parasitology Research, 98(1), 15–21. https://doi.org/10.1007/s00436-005-0050-9

26. Zhou, Z., et al. (2017). Deep reinforcement learning for de-novo drug design. arXiv preprint, arXiv:1711.10907. https://arxiv.org/abs/1711.10907